Published in Diabetes Care on February 01, 2005
Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT | NCT05095532
Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care (2009) 2.06
The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med (2013) 1.50
A new enzyme mixture to increase the yield and transplant rate of autologous and allogeneic human islet products. Transplantation (2012) 1.30
Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care (2009) 1.20
Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience. Acta Diabetol (2014) 1.05
Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3). J Clin Endocrinol Metab (2012) 1.01
Stem cells as a therapeutic target for diabetes. Front Biosci (Landmark Ed) (2010) 0.96
Advances and challenges in islet transplantation: islet procurement rates and lessons learned from suboptimal islet transplantation. J Transplant (2011) 0.90
Islet cell transplantation. Postgrad Med J (2007) 0.88
Potential of protein phosphatase inhibitor 1 as biomarker of pancreatic β-cell injury in vitro and in vivo. Diabetes (2013) 0.85
Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients. Am J Transplant (2012) 0.84
Continuous glucose monitoring system for early detection of graft dysfunction in allogenic islet transplant recipients. Transplant Proc (2006) 0.82
Cluster analysis of self-monitoring blood glucose assessments in clinical islet cell transplantation for type 1 diabetes. Diabetes Care (2011) 0.82
Assessment of islet function following islet and pancreas transplantation. Curr Diab Rep (2006) 0.81
Use of glucagon-like peptide-1 agonists to improve islet graft performance. Curr Diab Rep (2013) 0.77
Continuous glucose monitoring analysis as predictor of islet yield and insulin requirements in autologous islet transplantation after complete pancreatectomy. J Diabetes Sci Technol (2014) 0.77
Islet transplantation from a nationally funded UK centre reaches socially deprived groups and improves metabolic outcomes. Diabetologia (2015) 0.77
Serum C-peptide assay of patients with hyperglycemic emergencies at the Lagos State University Teaching Hospital (LASUTH), Ikeja. Int Arch Med (2014) 0.77
Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients. Diabetes Care (2013) 0.76
Pancreatic islet transplantation. Diabetol Metab Syndr (2009) 0.76
Single-donor islet transplantation in type 1 diabetes: patient selection and special considerations. Diabetes Metab Syndr Obes (2017) 0.75
Residual β-Cell Function Predicts Clinical Response After Autologous Hematopoietic Stem Cell Transplantation. Stem Cells Transl Med (2016) 0.75
CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Diabetologia (2015) 0.75
Validation of the BETA-2 Score: An Improved Tool to Estimate Beta Cell Function After Clinical Islet Transplantation Using a Single Fasting Blood Sample. Am J Transplant (2016) 0.75
Outcomes of Pancreatic Islet Allotransplantation Using the Edmonton Protocol at the University of Chicago. Transplant Direct (2016) 0.75
International trial of the Edmonton protocol for islet transplantation. N Engl J Med (2006) 13.43
Five-year follow-up after clinical islet transplantation. Diabetes (2005) 7.86
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology (2010) 3.54
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 2.51
Beta-cell differentiation from nonendocrine epithelial cells of the adult human pancreas. Nat Med (2006) 2.41
Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes (2002) 2.36
Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes (2009) 2.31
Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes (2004) 2.22
Cell encapsulation: promise and progress. Nat Med (2003) 2.18
A human beta-cell line for transplantation therapy to control type 1 diabetes. Nat Biotechnol (2005) 2.12
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Islet graft assessment in the Edmonton Protocol: implications for predicting long-term clinical outcome. Diabetes (2004) 1.98
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant (2007) 1.78
Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines. PLoS One (2012) 1.76
Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes (2002) 1.61
Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass. J Clin Endocrinol Metab (2005) 1.61
Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl Int (2009) 1.58
BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J Leukoc Biol (2009) 1.53
Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes (2004) 1.46
Edmonton's islet success has indeed been replicated elsewhere. Lancet (2003) 1.45
Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device. Transplantation (2015) 1.44
A novel approach to increase human islet cell mass while preserving beta-cell function. Diabetes (2002) 1.43
Cyclosporine treatment improves cardiac function and systemic hemodynamics during resuscitation in a newborn piglet model of asphyxia: a dose-response study. Crit Care Med (2012) 1.42
Update on islet transplantation. Cold Spring Harb Perspect Med (2012) 1.40
Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology (2003) 1.34
Strategic opportunities in clinical islet transplantation. Transplantation (2005) 1.34
Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes (2002) 1.32
Expansion of mesenchymal stem cells from human pancreatic ductal epithelium. Lab Invest (2006) 1.28
Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant (2007) 1.27
Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab (2003) 1.26
Current status of clinical islet cell transplantation. Methods Mol Biol (2006) 1.25
Portal venous pressure changes after sequential clinical islet transplantation. Transplantation (2002) 1.24
Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am J Transplant (2005) 1.23
Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes (2006) 1.21
Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health Workshop on Beta Cell Imaging. Transplantation (2004) 1.17
Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant (2008) 1.16
Enhancing the success of human islet isolation through optimization and characterization of pancreas dissociation enzyme. Am J Transplant (2007) 1.14
The portal immunosuppressive storm: relevance to islet transplantation? Ther Drug Monit (2005) 1.14
Estimation of pancreas weight from donor variables. Cell Transplant (2006) 1.13
Synaptosome-associated protein of 25 kilodaltons modulates Kv2.1 voltage-dependent K(+) channels in neuroendocrine islet beta-cells through an interaction with the channel N terminus. Mol Endocrinol (2002) 1.13
Islet isolation and transplantation outcomes of pancreas preserved with University of Wisconsin solution versus two-layer method using preoxygenated perfluorocarbon. Transplantation (2006) 1.12
Histologic graft assessment after clinical islet transplantation. Transplantation (2009) 1.12
XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes (2005) 1.12
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Glucose regulates cyclin D2 expression in quiescent and replicating pancreatic β-cells through glycolysis and calcium channels. Endocrinology (2011) 1.11
Current status of pancreatic islet transplantation. Clin Sci (Lond) (2006) 1.11
Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation (2010) 1.10
Advances in pancreatic islet transplantation in humans. Diabetes Obes Metab (2006) 1.08
Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther (2006) 1.08
The standardization of pancreatic donors for islet isolations. Transplantation (2005) 1.07
Comparison of human islet isolation outcomes using a new mammalian tissue-free enzyme versus collagenase NB-1. Transplantation (2010) 1.06
Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes (2006) 1.05
Revascularization of transplanted pancreatic islets and role of the transplantation site. Clin Dev Immunol (2013) 1.04
Impact of surgeon training on outcomes after resective hepatic surgery. Ann Surg Oncol (2008) 1.04
Factors influencing the collagenase digestion phase of human islet isolation. Transplantation (2007) 1.03
Surgical aspects of human islet isolation. Islets (2010) 1.03
Circumportal pancreas and islet isolation. Surgery (2008) 1.03
Comparison of the [13C]glucose breath test to the hyperinsulinemic-euglycemic clamp when determining insulin resistance. Diabetes Care (2004) 1.02
Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs (2004) 1.01
Comparison of aortic valve allograft decellularization techniques in the rat. J Biomed Mater Res A (2006) 1.01
Estrogen can prevent or reverse obesity and diabetes in mice expressing human islet amyloid polypeptide. Diabetes (2002) 1.00
Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int (2008) 1.00
Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant (2004) 1.00
Risks and side effects of islet transplantation. Curr Diab Rep (2004) 1.00
Beta-cell transplantation for diabetes therapy. Lancet (2008) 0.99
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer (2004) 0.99
Current indications for pancreas or islet transplant. Diabetes Obes Metab (2006) 0.98
Technical aspects of islet preparation and transplantation. Transpl Int (2003) 0.98